JPMorgan Chase & Co’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $230K | Buy |
57,434
+26,263
| +84% | +$105K | ﹤0.01% | 4406 |
|
|
2025
Q1 | $28.4K | Sell |
31,171
-97,701
| -76% | -$88.9K | ﹤0.01% | 5187 |
|
|
2024
Q4 | $357K | Buy |
128,872
+99,944
| +345% | +$277K | ﹤0.01% | 4298 |
|
|
2024
Q3 | $151K | Buy |
28,928
+6,851
| +31% | +$35.8K | ﹤0.01% | 4567 |
|
|
2024
Q2 | $98.5K | Sell |
22,077
-39,500
| -64% | -$176K | ﹤0.01% | 4603 |
|
|
2024
Q1 | $472K | Buy |
61,577
+27,241
| +79% | +$209K | ﹤0.01% | 3994 |
|
|
2023
Q4 | $146K | Buy |
34,336
+12,336
| +56% | +$52.6K | ﹤0.01% | 4603 |
|
|
2023
Q3 | $92.4K | Sell |
22,000
-4,305
| -16% | -$18.1K | ﹤0.01% | 4654 |
|
|
2023
Q2 | $147K | Buy |
26,305
+26,245
| +43,742% | +$146K | ﹤0.01% | 4452 |
|
|
2023
Q1 | $0 | Hold |
60
| – | – | ﹤0.01% | 5970 |
|
|
2022
Q4 | $0 | Hold |
60
| – | – | ﹤0.01% | 5755 |
|
|
2022
Q3 | $0 | Hold |
60
| – | – | ﹤0.01% | 5665 |
|
|
2022
Q2 | $0 | Sell |
60
-310,873
| -100% | – | ﹤0.01% | 5746 |
|
|
2022
Q1 | $1.27M | Sell |
310,933
-13,454
| -4% | -$55K | ﹤0.01% | 3469 |
|
|
2021
Q4 | $2.21M | Sell |
324,387
-7,504
| -2% | -$51.2K | ﹤0.01% | 3168 |
|
|
2021
Q3 | $3.85M | Buy |
331,891
+315,232
| +1,892% | +$3.65M | ﹤0.01% | 2763 |
|
|
2021
Q2 | $284K | Sell |
16,659
-4,665
| -22% | -$79.5K | ﹤0.01% | 4313 |
|
|
2021
Q1 | $422K | Buy |
21,324
+17,488
| +456% | +$346K | ﹤0.01% | 4132 |
|
|
2020
Q4 | $79K | Buy |
3,836
+807
| +27% | +$16.6K | ﹤0.01% | 4356 |
|
|
2020
Q3 | $72K | Buy |
+3,029
| New | +$72K | ﹤0.01% | 4182 |
|